Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Homology Medicines, Inc. operates as a genetic medicines company. The Company offers a platform to utilize human hematopoietic stem cell derived adeno-associated virus vectors to treat a range of disease-causing mutations through gene correction, insertion, and knockout. Homology Medicines serves patients in the United States.
Website: homologymedicines.com



Growth: Bad revenue growth rate -50.0%, there is slowdown compared to average historical growth rates 50.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +80.0%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.36 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -86.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 76.1% higher than minimum and 68.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.5x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FIXX
Share price, USD:  (0.0%)0.9347
year average price 0.9347  


year start price 0.9347 2024-07-27

min close price 0.9347 2024-07-27

max close price 0.9366 2024-10-29

current price 0.9347 2025-07-26
Common stocks: 58 017 411

Dividend Yield:  0.0%
FCF Yield LTM: -86.7%
EV / LTM EBITDA: 500.0x
EV / Sales: -19.6x
Margin (EBITDA LTM / Revenue): 80.0%
Fundamental value created in LTM:
Market Cap ($m): 54
Net Debt ($m): -152
EV (Enterprise Value): -98
Price to Book: 1.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-05-11Zacks Investment Research

Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-03-13 2023-11-14 2023-08-14 2023-05-11 2023-03-09 2022-11-10
acceptedDate 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 1M 0 354 000 802 000 802 000 802 000
costOfRevenue 0 1M 136 000 564 000 0 0 0
grossProfit 0 131 000 -136 000 -210 000 802 000 802 000 802 000
grossProfitRatio 0 0.092 0 -0.593 1 1 1
researchAndDevelopmentExpenses 10M 2M 18M 23M 20M 27M 26M
generalAndAdministrativeExpenses 5M 8M 7M 8M 8M 8M 8M
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 8M 7M 8M 8M 8M 8M
otherExpenses 0 3M 7M 0 0 0 0
operatingExpenses 15M 9M 31M 31M 28M 35M 34M
costAndExpenses 15M 9M 31M 31M 28M 35M 34M
interestIncome 0 1M 1M 2M 1M 1M 1M
interestExpense 0 1M 0 0 -1M -2M 1M
depreciationAndAmortization 29 000 43 812 136 000 217 000 225 000 296 000 321 000
ebitda -15M -1M -31M -31M -27M -34M -33M
ebitdaratio 0 -6.639 0 -86.438 -34.022 -42.641 -40.575
operatingIncome -15M -9M -31M -31M -28M -34M -33M
operatingIncomeRatio 0 -6.639 0 -87.051 -34.303 -43.01 -40.975
totalOtherIncomeExpensesNet 16M 7M 1M 2M 1M 1M 1M
incomeBeforeTax 1M -2M -30M -29M -26M -33M -32M
incomeBeforeTaxRatio 0 -1.52 0 -82.782 -32.471 -41.196 -39.393
incomeTaxExpense 176 000 14M 3M 6M 3M -101 000 -46 000
netIncome 1M -16M -33M -35M -29M -33M -32M
netIncomeRatio 0 -11.367 0 -98.994 -35.965 -41.07 -39.335
eps 1.03 -50.01 -0.57 -0.61 -0.5 -0.57 -0.55
epsdiluted 0.44 -50.01 -0.57 -0.61 -0.5 -0.57 -0.55
weightedAverageShsOut 995 280 322 318 58M 58M 58M 57M 57M
weightedAverageShsOutDil 2M 322 318 58M 58M 58M 57M 57M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-03-13 2023-11-14 2023-08-14 2023-05-11 2023-03-09 2022-11-10
acceptedDate 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 116M 39M 29M 77M 39M 34M 43M
shortTermInvestments 20M 43M 74M 50M 111M 141M 158M
cashAndShortTermInvestments 135M 83M 103M 127M 150M 175M 201M
netReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
otherCurrentAssets 3M 1M 3M 4M 4M 6M 12M
totalCurrentAssets 138M 84M 107M 131M 154M 181M 213M
propertyPlantEquipmentNet 8M 650 000 19M 21M 21M 22M 22M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 14M 17M 23M 26M 27M
taxAssets 0 222M 0 0 0 0 0
otherNonCurrentAssets 6M 0 0 -38M 0 0 0
totalNonCurrentAssets 14M 222M 33M 38M 44M 47M 49M
otherAssets 0 0 0 0 0 0 0
totalAssets 152M 306M 140M 169M 198M 228M 263M
accountPayables 5M 3M 8M 3M 4M 1M 5M
shortTermDebt 3M 1M 2M 2M 2M 2M 1M
taxPayables 0 0 0 0 0 0 816 000
deferredRevenue 0 0 0 0 354 000 1M 2M
otherCurrentLiabilities 25M 7M 16M 18M 13M 19M 17M
totalCurrentLiabilities 33M 12M 25M 23M 19M 23M 25M
longTermDebt 6M 0 27M 27M 27M 28M 28M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 222M 0 0 0 0 0
otherNonCurrentLiabilities 65M -222M 0 0 0 0 20M
totalNonCurrentLiabilities 71M 222M 27M 27M 27M 28M 28M
otherLiabilities 0 1 0 0 0 0 0
capitalLeaseObligations 0 0 28M 29M 29M 29M 30M
totalLiabilities 104M 233M 52M 50M 46M 50M 54M
preferredStock 152M 0 0 0 0 0 0
commonStock 2000 6000 6000 6000 6000 6000 6000
retainedEarnings -186M -542M -526M -493M -458M -429M -395M
accumulatedOtherComprehensiveIncomeLoss -5000 -5000 -36 000 -88 000 -182 000 -404 000 -457 000
othertotalStockholdersEquity 82M 615M 614M 612M 610M 608M 604M
totalStockholdersEquity 49M 73M 88M 119M 152M 178M 209M
totalEquity 49M 73M 88M 119M 152M 178M 209M
totalLiabilitiesAndStockholdersEquity 152M 306M 140M 169M 198M 228M 263M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 152M 306M 140M 169M 198M 228M 263M
totalInvestments 20M 43M 74M 50M 111M 167M 185M
totalDebt 9M 1M 28M 29M 29M 29M 30M
netDebt -106M -38M -773 000 -48M -10M -5M -13M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-03-13 2023-11-14 2023-08-14 2023-05-11 2023-03-09 2022-11-10
acceptedDate 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47
calendarYear 2024 2023 2023 2023 2023 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1M -16M -33M -35M -29M -34M -34M
depreciationAndAmortization 29 000 0 136 000 217 000 225 000 296 000 321 000
deferredIncomeTax 0 -8M 3M 5M 0 0 0
stockBasedCompensation 417 000 847 000 2M 2M 2M 3M 3M
changeInWorkingCapital 0 -12M 3M 3M -2M 3M 4M
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables 928 000 -5M 4M -242 000 2M -4M 1M
otherWorkingCapital 0 -7M -1M 4M -5M 7M 3M
otherNonCashItems 0 5M 365 000 364 000 2M 668 000 2M
netCashProvidedByOperatingActivities -15M -22M -25M -24M -26M -27M -25M
investmentsInPropertyPlantAndEquipment 0 338 000 -338 000 0 -228 000 -9000 -6000
acquisitionsNet 0 216 000 338 000 0 0 -130M 0
purchasesOfInvestments 0 0 -48M 1000 -25M 0 -108M
salesMaturitiesOfInvestments 97 000 32M 25M 61M 57M 18M 0
otherInvestingActivites 0 -31M 338 000 0 0 130M 0
netCashUsedForInvestingActivites 97 000 32M -23M 61M 31M 18M -108M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 42M 14 000 18 000 2000 0 1000 0
commonStockRepurchased 0 0 0 0 150 000 595 000 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 99M 14 000 0 0 0 -564 000 124 000
netCashUsedProvidedByFinancingActivities 99M 14 000 18 000 2000 150 000 32 000 124 000
effectOfForexChangesOnCash 0 -15M 15M 0 0 0 0
netChangeInCash 85M 10M -48M 37M 5M -9M -133M
cashAtEndOfPeriod 116M 39M 29M 77M 39M 34M 43M
cashAtBeginningOfPeriod 31M 29M 77M 39M 34M 43M 176M
operatingCashFlow -15M -22M -25M -24M -26M -27M -25M
capitalExpenditure 0 338 000 -338 000 0 -228 000 -9000 -6000
freeCashFlow -15M -21M -25M -24M -26M -27M -25M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-18 20:30 ET
Homology Medicines Declares Distribution to Common Stockholders
2024-01-03 21:08 ET
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
2023-11-16 12:05 ET
Q32 Bio and Homology Medicines Announce Merger Agreement
2023-11-16 12:05 ET
Q32 Bio and Homology Medicines Announce Merger Agreement
2023-11-14 21:33 ET
Homology Medicines Reports Third Quarter 2023 Financial Results
2023-08-14 20:05 ET
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
2023-07-27 20:05 ET
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
2023-07-27 20:01 ET
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
2023-05-16 12:00 ET
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
2023-05-11 20:05 ET
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
2023-05-03 11:30 ET
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
2023-03-15 20:01 ET
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
2023-03-09 21:05 ET
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
2023-03-09 13:00 ET
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
2023-03-02 12:30 ET
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
2023-02-22 21:01 ET
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
2023-01-04 21:01 ET
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
2022-11-10 21:07 ET
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
2022-10-27 13:00 ET
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
2022-10-06 12:30 ET
Homology Medicines to Participate at Upcoming Conferences
2022-09-06 20:01 ET
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
2022-08-15 20:10 ET
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
2022-08-11 20:05 ET
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
2022-07-05 12:30 ET
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
2022-06-29 12:00 ET
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
2022-06-13 12:00 ET
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
2022-05-18 10:00 ET
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
2022-05-16 20:15 ET
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
2022-05-02 20:56 ET
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
2022-04-21 12:30 ET
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
2022-03-23 20:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
2022-03-10 21:01 ET
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
2022-03-03 12:30 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2022-02-18 21:05 ET
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
2022-02-10 16:40 ET
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting
2022-01-28 07:30 ET
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
2021-11-15 12:10 ET
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
2021-11-03 12:28 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2021-10-21 11:00 ET
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
2021-10-20 12:30 ET
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
2021-10-18 12:30 ET
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
2021-10-12 20:05 ET
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
2021-08-12 20:05 ET
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
2021-08-05 12:30 ET
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
2021-08-04 12:30 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2021-05-13 11:00 ET
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
2021-05-06 20:05 ET
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
2021-05-03 12:00 ET
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
2021-04-28 12:00 ET
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model
2021-04-14 12:30 ET
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
2021-04-12 12:30 ET
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
2021-04-07 12:52 ET
Homology Medicines Announces Pricing of Public Offering of Common Stock
2021-04-06 20:19 ET
Homology Medicines Announces Proposed Public Offering of Common Stock
2021-03-11 21:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
2021-03-01 12:30 ET
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
2021-02-25 13:00 ET
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
2021-02-08 19:50 ET
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
2021-01-06 13:00 ET
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
2020-11-09 21:05 ET
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
2020-11-09 13:00 ET
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
2020-11-06 16:40 ET
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
2020-11-05 14:15 ET
Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU
2020-10-22 12:30 ET
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
2020-09-18 13:00 ET
Homology Medicines to Participate in Upcoming Conferences
2020-08-10 20:05 ET
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
2020-07-21 12:00 ET
Homology Medicines Appoints Jeff Poulton to the Board of Directors
2020-05-26 18:10 ET
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program
2020-05-12 12:00 ET
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting
2020-05-07 20:05 ET
Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
2020-04-29 12:00 ET
Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting
2020-03-16 13:00 ET
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model
2020-03-12 20:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
2020-02-20 14:00 ET
Homology Medicines to Participate in Upcoming Investor and Scientific Conferences
2020-02-13 14:00 ET
Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders
2019-12-17 21:01 ET
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU
2019-12-16 14:00 ET
Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care
2019-12-03 13:30 ET
Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer
2019-11-26 20:00 ET
Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs
2019-11-12 21:09 ET
Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-25 12:30 ET
Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision
2019-10-21 12:30 ET
Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies
2019-09-30 12:49 ET
Homology Medicines to Participate in Conferences in October
2019-04-04 20:05 ET
Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production
2019-04-04 11:00 ET
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
2019-03-19 12:39 ET
Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day
2019-03-12 11:13 ET
Homology Medicines Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Recent Accomplishments
2019-03-06 13:30 ET
Homology Medicines to Present at Cowen Healthcare Conference
2019-01-07 14:25 ET
Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019

SEC forms

Show financial reports only

SEC form 10
2025-05-08 11:11 ET
Homology Medicines reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Homology Medicines reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Homology Medicines published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Homology Medicines reported for 2025 q1
SEC form 10
2025-03-11 11:18 ET
Homology Medicines reported for 2024 q4
SEC form 10
2025-03-11 00:00 ET
Homology Medicines reported for 2024 q4
SEC form 8
2025-03-11 00:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-03-11 00:00 ET
Homology Medicines reported for 2024 q4
SEC form 8
2025-03-10 11:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-03-10 11:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-02-10 21:14 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-02-10 21:14 ET
Homology Medicines published news for 2024 q4
SEC form 10
2024-11-07 07:16 ET
Homology Medicines reported for 2024 q3
SEC form 8
2024-11-07 07:05 ET
Homology Medicines reported for 2024 q3
SEC form 8
2024-11-07 07:05 ET
Homology Medicines published news for 2024 q3
SEC form 8
2024-08-08 00:00 ET
Homology Medicines published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Homology Medicines reported for 2024 q2
SEC form 8
2024-08-08 00:00 ET
Homology Medicines published news for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Homology Medicines published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Homology Medicines published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Homology Medicines reported for 2024 q1
SEC form 10
2024-03-13 00:00 ET
Homology Medicines reported for 2023 q4
SEC form 10
2024-03-12 21:56 ET
Homology Medicines reported for 2023 q4
SEC form 10
2023-11-14 16:00 ET
Homology Medicines reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Homology Medicines reported for 2023 q3
SEC form 10
2023-08-14 16:01 ET
Homology Medicines reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Homology Medicines reported for 2023 q2
SEC form 6
2023-07-27 17:29 ET
Homology Medicines published news for 2023 q2
SEC form 6
2023-06-15 19:25 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:33 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:17 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:04 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-14 16:06 ET
Homology Medicines published news for 2023 q1
SEC form 10
2023-05-11 16:00 ET
Homology Medicines reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Homology Medicines reported for 2023 q1
SEC form 6
2023-04-28 16:00 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-03-16 17:03 ET
Homology Medicines published news for 2022 q4
SEC form 10
2023-03-09 16:01 ET
Homology Medicines reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Homology Medicines reported for 2022 q4
SEC form 6
2023-01-04 17:07 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:37 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:36 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:34 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:32 ET
Homology Medicines published news for 2022 q4
SEC form 10
2022-11-10 16:01 ET
Homology Medicines reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Homology Medicines reported for 2022 q3
SEC form 6
2022-09-08 16:05 ET
Homology Medicines published news for 2022 q2
SEC form 6
2022-09-08 16:03 ET
Homology Medicines published news for 2022 q2
SEC form 10
2022-08-15 16:04 ET
Homology Medicines reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Homology Medicines reported for 2022 q2
SEC form 6
2022-06-16 16:05 ET
Homology Medicines published news for 2022 q1
SEC form 6
2022-06-13 08:20 ET
Homology Medicines published news for 2022 q1
SEC form 10
2022-05-16 16:03 ET
Homology Medicines reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Homology Medicines reported for 2022 q1
SEC form 6
2022-04-29 16:04 ET
Homology Medicines published news for 2022 q1
SEC form 6
2022-04-21 17:20 ET
Homology Medicines published news for 2022 q1
SEC form 10
2022-03-23 16:01 ET
Homology Medicines published news for 2021 q4
SEC form 10
2022-03-23 00:00 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-16 16:06 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-02-18 16:16 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-02-02 17:36 ET
Homology Medicines published news for 2021 q4
SEC form 10
2021-11-15 07:01 ET
Homology Medicines published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Homology Medicines published news for 2021 q3
SEC form 10
2021-08-12 16:02 ET
Homology Medicines published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Homology Medicines published news for 2021 q2
SEC form 6
2021-06-21 17:02 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-05-06 16:02 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-29 16:01 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-12 16:05 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-09 16:45 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-03-11 16:04 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-03-01 17:02 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-02-08 16:07 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-01-06 08:01 ET
Homology Medicines published news for 2020 q4
SEC form 6
2020-12-18 16:01 ET
Homology Medicines published news for 2020 q3
SEC form 10
2020-11-09 16:02 ET
Homology Medicines published news for 2020 q3
SEC form 6
2020-11-09 08:26 ET
Homology Medicines published news for 2020 q3